MK 1972
Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck Sharp & Dohme
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections in Germany (PO, Capsule)
- 30 Jan 2012 Merck terminates a phase I trial in treatment-naive HIV-1 infections in Germany (NCT01353898)
- 19 Sep 2011 Merck suspends phase I trial in treatment-naive HIV-1 infections in Germany (NCT01353898)